Cargando…
Carbimazole-induced cholestatic hepatitis in Graves’ disease
Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683215/ https://www.ncbi.nlm.nih.gov/pubmed/23776913 http://dx.doi.org/10.4103/2230-8210.109660 |
_version_ | 1782273473392934912 |
---|---|
author | Kota, Sunil K. Meher, Lalit K. Kota, Siva K. Jammula, Sruti Modi, Kirtikumar D. |
author_facet | Kota, Sunil K. Meher, Lalit K. Kota, Siva K. Jammula, Sruti Modi, Kirtikumar D. |
author_sort | Kota, Sunil K. |
collection | PubMed |
description | Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves’ disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely. |
format | Online Article Text |
id | pubmed-3683215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-36832152013-06-17 Carbimazole-induced cholestatic hepatitis in Graves’ disease Kota, Sunil K. Meher, Lalit K. Kota, Siva K. Jammula, Sruti Modi, Kirtikumar D. Indian J Endocrinol Metab Case Report Antithyroid medications are one of the treatment options for Graves’ disease. Carbimazole is widely used as the drug of choice, except in pregnancy, where propythiouracil is preferred by many. It is generally well-tolerated. Its side-effects include allergy, upper gastrointestinal upset, a rare occurrence of granulocytosis, and others. Hepatitis is another rare, but serious side-effect. We report a healthy 30-year-old male patient with Graves’ disease, who developed cholestatic jaundice after Carbimazole therapy for four months. He made a full recovery after the drug was discontinued. An idiosyncratic mechanism seemed likely. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3683215/ /pubmed/23776913 http://dx.doi.org/10.4103/2230-8210.109660 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kota, Sunil K. Meher, Lalit K. Kota, Siva K. Jammula, Sruti Modi, Kirtikumar D. Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title | Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title_full | Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title_fullStr | Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title_full_unstemmed | Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title_short | Carbimazole-induced cholestatic hepatitis in Graves’ disease |
title_sort | carbimazole-induced cholestatic hepatitis in graves’ disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3683215/ https://www.ncbi.nlm.nih.gov/pubmed/23776913 http://dx.doi.org/10.4103/2230-8210.109660 |
work_keys_str_mv | AT kotasunilk carbimazoleinducedcholestatichepatitisingravesdisease AT meherlalitk carbimazoleinducedcholestatichepatitisingravesdisease AT kotasivak carbimazoleinducedcholestatichepatitisingravesdisease AT jammulasruti carbimazoleinducedcholestatichepatitisingravesdisease AT modikirtikumard carbimazoleinducedcholestatichepatitisingravesdisease |